Whole genome sequence to decipher the resistome of Shewanella algae,a multidrug-resistant bacterium responsible for pneumonia,Marseille, France

We characterize and decipher the resistome and the virulence factors of Shewanella algae MARS 14, a multidrug-resistant clinical strain using the whole genome sequencing (WGS) strategy. The bacteria were isolated from the bronchoalveolar lavage of a hospitalized patient in the Timone Hospital in Marseille, France who developed pneumonia after plunging into the Mediterranean Sea. Results: The genome size of S. algae MARS 14 was 5,005,710 bp with 52.8% guanine cytosine content. The resistome includes members of class C and D beta-lactamases and numerous multidrug-efflux pumps. We also found the presence of several hemolysins genes, a complete flagellum system gene cluster and genes responsible for biofilm formation. Moreover, we reported for the first time in a clinical strain of Shewanella spp. the presence of a bacteriocin (marinocin). Conclusion: The WGS analysis of this pathogen provides insight into its virulence factors and resistance to antibiotics.     

阴道来源的乳杆菌抑菌物质研究进展

乳杆菌是大多数健康女性阴道微生态中的优势菌群,对预防泌尿生殖系统感染性疾病起重要作用。能产生乳酸、过氧化氢、细菌素和生物表面活性物质等抑菌物质是乳杆菌成为潜在益生菌的重要基础。本文对阴道来源的乳杆菌抑菌物质相关研究进展作一综述。     

牙菌斑生物膜的细菌生长抑制因子

牙菌斑生物膜中的细菌是龋病发生的先决条件,而口腔内存在多种细菌生长的抑制因子,它们对细菌的生长或菌斑的形成起一定抑制作用。细菌生长的抑制因子主要来自宿主和细菌本身产生的细菌素以及其他代谢产物,本文就致龋菌生长抑制因子的种类及作用的研究进展作一综述。     

From the Cover: Thuricin CD,a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile

The last decade has seen numerous outbreaks of Clostridium difficile-associated disease (CDAD), which presented significant challenges for healthcare facilities worldwide. We have identified and purified thuricin CD, a two-component antimicrobial that shows activity against C. difficile in the nanomolar range. Thuricin CD is produced by Bacillus thuringiensis DPC 6431, a bacterial strain isolated from a human fecal sample, and it consists of two distinct peptides, Trn-α and Trn-β, that act synergistically to kill a wide range of clinical C. difficile isolates, including ribotypes commonly associated with CDAD (e.g., ribotype 027). However, this bacteriocin thuricin CD has little impact on most other genera, including many gastrointestinal commensals. Complete amino acid sequencing using infusion tandem mass spectrometry indicated that each peptide is posttranslationally modified at its respective 21st, 25th, and 28th residues. Solution NMR studies on [¹³C,¹⁵N] Trn-α and [¹³C,¹⁵N]Trn-β were used to characterize these modifications. Analysis of multidimensional NOESY data shows that specific cysteines are linked to the α-carbons of the modified residues, forming three sulfur to α-carbon bridges. Complete sequencing of the thuricin CD gene cluster revealed genes capable of encoding two S′-adenosylmethionine proteins that are characteristically associated with unusual posttranslational modifications. Thuricin CD is a two-component antimicrobial peptide system with sulfur to α-carbon linkages, and it may have potential as a targeted therapy in the treatment of CDAD while also reducing collateral impact on the commensal flora.     

Gut microbiota as a source of novel antimicrobials

Bacteria, Archaea, Eukarya and viruses coexist in the human gut, and this coexistence is functionally balanced by symbiotic or antagonistic relationships. Antagonism is often characterized by the production of antimicrobials against other organisms occupying the same environmental niche. Indeed, close co-evolution in the gut has led to the development of specialized antimicrobials, which is attracting increased attention as these may serve as novel alternatives to antibiotics and thereby help to address the global problem of antimicrobial resistance. The gastrointestinal (GI) tract is especially suitable for finding novel antimicrobials due to the vast array of microbes that inhabit it, and a considerable number of antimicrobial producers of both wide and narrow spectrum have been described. In this review, we summarize some of the antimicrobial compounds that are produced by bacteria isolated from the gut environment, with a special focus on bacteriocins. We also evaluate the potential therapeutic application of these compounds to maintain homeostasis in the gut and the biocontrol of pathogenic bacteria.     

Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection

Listeria monocytogenes is responsible for gastroenteritis in healthy individuals and for a severe invasive disease in immunocompromised patients. Among the three identified L. monocytogenes evolutionary lineages, lineage I strains are overrepresented in epidemic listeriosis outbreaks, but the mechanisms underlying the higher virulence potential of strains of this lineage remain elusive. Here, we demonstrate that Listeriolysin S (LLS), a virulence factor only present in a subset of lineage I strains, is a bacteriocin highly expressed in the intestine of orally infected mice that alters the host intestinal microbiota and promotes intestinal colonization by L. monocytogenes, as well as deeper organ infection. To our knowledge, these results therefore identify LLS as the first bacteriocin described in L. monocytogenes and associate modulation of host microbiota by L. monocytogenes epidemic strains to increased virulence.The gram-positive bacterium Listeria monocytogenes is a facultative intracellular pathogen that causes foodborne infections in humans and animals. Upon consumption of contaminated food, L. monocytogenes reaches the intestinal lumen, crosses the intestinal barrier, and disseminates within the host. The clinical manifestations of listeriosis vary from a mild, self-limiting gastroenteritis to severe intestinal and systemic infections, with a fatality rate estimated to 20–30% of infected individuals (1). Host gut microbiota plays a critical role in resistance against colonization by invading pathogens within the intestine (2). The mechanisms of L. monocytogenes to compete with the host microbiota to survive in the intestine remain unknown.During the last decades, the majority of Listeria studies in bacterial pathophysiology, cell biology, and immunology compared three pathogenic strains from lineage II: EGD, EGD-e, and 10403S (3). Interestingly, major listeriosis epidemics have been preferentially associated to L. monocytogenes clonal groups belonging to the evolutionary lineage I and, more specifically, to serotype 4b (4, 5), but the molecular mechanisms that contribute to the higher virulence potential of these bacterial strains have not been identified yet.Bacteriocins are bacterially synthesized proteinaceous substances that target and inhibit the growth of closely related bacteria, allowing competition in diverse ecological niches, including the digestive tract (6, 7). Production of these antimicrobial peptides is widespread among bacterial species, and such production is made possible by biosynthetic machineries present in the genome, plasmids, or conjugative transposons (7). A conserved biosynthetic gene cluster for the production of bacteriocins displaying thiazole and oxazole heterocycles was discovered in 2008 in six microbial phyla (8). These gene clusters encode a toxin precursor and all indispensable proteins for toxin maturation in a mode similar to that associated with the bacteriocin microcin B17 (8). This gene cluster in L .monocytogenes was only present in a subset of lineage I strains responsible for the majority of Listeria epidemics (9). This L. monocytogenes toxin was designated Listeriolysin S (LLS) and was shown to produce a hemolytic and cytotoxic factor necessary for virulence in a murine intraperitoneal (i.p.) infection model (9).The aim of the present work was to understand where LLS is produced in a murine oral infection model, as well as to investigate the function of this virulence factor. Interestingly, to our knowledge, we show that LLS is the first bacteriocin described in L. monocytogenes. This toxin that is specifically expressed in the intestine augments host colonization.     

Effect of a bacteriocin-producing strain of Streptococcus sobrinus on infection and establishment of Streptococcus mutans on tooth surfaces in rats

The effect of bacteriocin produced by Streptococcus sobrinus MT6223 on infection and establishment of Streptococcus mutans MT6222 was studied in specific pathogen-free rats. These strains were isolated from a carious lesion of a single subject. S. mutans MT6222 was found to be susceptible to the growth inhibitory action of S. sobrinus MT6223. When simultaneously inoculated into the oral cavity of rats, even a small inoculum (10(5) CFU) of S. sobrinus MT6223 completely inhibited colonization of S. mutans MT6222 on the tooth surface. Also, S. sobrinus MT6223 eliminated S. mutans MT6222 when MT6223 (10(8) CFU) was inoculated 2 days after the inoculation of 10(8) CFU cells of MT6222. Similar results were obtained in dental plaque samples from the tooth surface and the fissures of the upper molars at the end of the experiment. However, when S. sobrinus MT6223 (10(8) CFU) was inoculated 2 weeks after the inoculation of S. mutans MT6222 (10(8) CFU), MT6223 coexisted with MT6222. However, the plaque samples showed that MT6223 inhibited the establishment of MT6222 on smooth surfaces, but not in fissures. In addition, MT6223 protected against subsequent infection with MT6222. However, a nonbacteriocinogenic mutant of S. sobrinus MT6223 did not inhibit the infection and establishment of S. mutans MT6222.     

Current strategies for improving food bacteria

Novel concepts and methodologies are emerging that hold great promise for the directed improvement of food-related bacteria, specifically lactic acid bacteria. Also, the battle against food spoilage and pathogenic bacteria can now be fought more effectively. Here we describe recent advances in microbial physiology and genomic research of these organisms that enable novel strategies for obtaining safe, healthy, and good-tasting fermented food products.     

The Bacteriocin Sublancin Attenuates Intestinal Injury in Young Mice Infected With Staphylococcus aureus

Sublancin, a bacteriocin, has bactericidal activity against a broad spectrum of gram‐positive bacteria. However, studies have not been conducted to determine its in vivo efficacy against potential pathogens. The objective of this study was to investigate the effects of sublancin in a Staphylococcus aureus (S. aureus) infected mouse model which induced intestinal injury. A total of 160, 4‐week‐old mice were randomly assigned to one of eight treatments. Mice in the control group were injected intraperitoneally with 0.5 mL of 0.9% saline. Mice in the other seven groups were given an intraperitoneal injection of 0.5 mL saline containing 1.0 × 10¹⁰ colony‐forming units (CFU)/mL S. aureus. Six hours after inoculation, mice in the control group were again injected with 0.5 mL of 0.9% saline. Mice in the other seven groups were injected intraperitoneally with 0.5 mL of 0.9% saline containing 0, 0.5, 1.0, 2.0, or 4.0 mg/kg body weight (BW) sublancin or 1.0 or 2.0 mg/kg BW ampicillin. The results showed that 4.0 mg/kg sublancin and 2.0 mg/kg ampicillin significantly reduced mice mortality from 55 to 10%. The height and the number of proliferated cells from the intestinal villi in the sublancin and ampicillin treated mice were higher than in the control. We conclude that sublancin has potent antibacterial activity against S. aureus. Therefore, sublancin could find use as an alternative antimicrobial agent for the treatment of gram‐positive bacterial infections. Anat Rec, 297:1454–1461, 2014. © 2014 Wiley Periodicals, Inc.